Yatharth Hospital & Trauma Care Services Limited — PPTs, 27-01-2025: Investor Presentation

**Financial Highlights**: Yatharth Hospital reported robust Q3 FY25 results, with revenues reaching ₹2,192 million, up 31% YoY. EBITDA improved by 18% YoY to ₹549 million, while the PAT showed a slight increase to ₹305 million, though margins contracted to 13.9%. For 9M FY25, total revenue climbed to ₹6,487 million, reflecting a growth of 32% YoY, with EBITDA growing 22% to ₹1,632 million. The occupancy rate across hospitals rose to 60% in Q3, contributing to improved ARPOB at ₹30,652, up 4% YoY.

**Strategic Initiatives and Growth Drivers**: Yatharth is expanding its footprint with recent acquisitions in New Delhi and Faridabad, adding significant capacity. These new facilities are set to operationalize by Q1 FY26, further bolstering the hospital chain’s position among the top players in North India.

**Business Developments**: The recent QIP raised ₹6,250 million, aimed at acquisitions and medical equipment purchases, indicating strong confidence from institutional investors. Notably, the Noida Extension hospital saw a 42% YoY revenue increase, demonstrating solid growth in operational performance.

**Market Position and Competitive Advantage**: With a bed capacity exceeding 2,300 and plans to increase it substantially, Yatharth is well-positioned to tap into the growing demand for healthcare services in an underserved North Indian market. The company is enhancing its service offerings, particularly in oncology, to sustain its competitive edge.

**Investor Implications**: Given the strong revenue growth and strategic expansion plans, Yatharth Hospital presents a positive outlook for investors. The successful capital raise alongside operational performance improvements enhances the potential for future growth, making it a stock to watch closely.